ProStrakan Launches Nordic Sales Joint Venture With Orexo

ProStrakan, a Scottish pharmaceutical company, announced that it has entered into a joint venture agreement with the Swedish pharmaceutical company, Orexo, to collaborate in the marketing and distribution of the current and future product portfolios of both ProStrakan and Orexo in Norway, Sweden, Finland, Denmark and Iceland.

According to ProStrakan and Orexo, ProStrakan’s existing Swedish affiliate, ProStrakan AB, will be used as the joint venture company.

Orexo said it is investing an approximate $2.6 million to acquire 50 percent of ProStrakan AB.

According to the companies, the portfolio of drugs will include Tostrex, Rectogesic, Droperidol, Rapinyl (for the management of breakthrough cancer pain, licensed from Orexo in 2005) and Sancuso (ProStrakan’s proprietary transdermal patch for the prevention of chemotherapy-induced nausea and vomiting).